Liposomal Doxorubicin in the treatment of breast cancer patients: a review - Wikidata - awgldk - TriplyDB

Liposomal Doxorubicin in the treatment of breast cancer patients: a review

Liposomal Doxorubicin in the treatment of breast cancer patients: a review

http://www.wikidata.org/entity/Q36748268

about

Efficacy and Cardiotoxicity of Liposomal Doxorubicin-Based Chemotherapy in Advanced Breast Cancer: A Meta-Analysis of Ten Randomized Controlled Trials Echogenic Glycol Chitosan Nanoparticles for Ultrasound-Triggered Cancer Theranostics Liposomes as nanomedical devices Low Intensity Ultrasound Mediated Liposomal Doxorubicin Delivery Using Polymer Microbubbles.Chemotherapy-Induced Cardiotoxicity: Pathophysiology and Prevention Non-pegylated liposomal Doxorubicin-cyclophosphamide in sequential regimens with taxanes as neoadjuvant chemotherapy in breast cancer patients.BP-C1 in the treatment of patients with stage IV breast cancer: a randomized, double-blind, placebo-controlled multicenter study and an additional open-label treatment phase.Physalin B not only inhibits the ubiquitin-proteasome pathway but also induces incomplete autophagic response in human colon cancer cells in vitro.Can Some Marine-Derived Fungal Metabolites Become Actual Anticancer Agents?HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.Extracellular vesicles and their synthetic analogues in aging and age-associated brain diseases.Building SuperModels: emerging patient avatars for use in precision and systems medicine Science and technology of the emerging nanomedicines in cancer therapy: A primer for physicians and pharmacists.Applications of nanoparticle drug delivery systems for the reversal of multidrug resistance in cancer.Biodegradable and Renal Clearable Inorganic Nanoparticles.Microfluidic technique to measure intratumoral transport and calculate drug efficacy shows that binding is essential for doxorubicin and release hampers Doxil.Pegylated liposomal Doxorubicin-induced acute transient encephalopathy in a patient with breast cancer: a case report.Tumor Targeting via Integrin Ligands.Nanooncology: the future of cancer diagnosis and therapy.Silencing the roadblocks to effective triple-negative breast cancer treatments by siRNA nanoparticles.The most prevalent side effects of pegylated liposomal doxorubicin monotherapy in women with metastatic breast cancer: a systematic review of clinical trials.Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention.Cationic Polymethacrylate-Modified Liposomes Significantly Enhanced Doxorubicin Delivery and Antitumor Activity.Delivery of epirubicin via slow infusion as a strategy to mitigate chemotherapy-induced cardiotoxicity.Multiphoton fluorescence lifetime imaging of chemotherapy distribution in solid tumors.Role of a novel benzoxazine derivative in the chemosensitization of colon cancer.Calcium modulation of doxorubicin cytotoxicity in yeast and human cells.Ex Vivo Cardiotoxicity of Antineoplastic Casiopeinas Is Mediated through Energetic Dysfunction and Triggered Mitochondrial-Dependent Apoptosis.Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes.γδ T Cells and Tumor Microenvironment: From Immunosurveillance to Tumor Evasion.Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer

P2860

Q26800140-15E7F317-4584-4C34-BB8C-C64F3BC8F1AD Q27300964-68093A6E-0A41-4D3C-86FA-25ED0896DEFA Q28088315-6D759015-80D0-4114-9BFD-FB66C55417A1 Q30359572-B2B14E06-7C19-4DBF-9FE7-EDF0141608AC Q30399577-41984790-867D-47DB-8C50-30A5029120D6 Q33634964-643C585C-8F98-4C16-918E-8FBB7432CB83 Q34609443-A460AD56-58CF-435B-8BD3-0A747755D5C3 Q35289448-8674C189-6037-4B45-A806-08D2C08058F0 Q35790810-1CC332DE-6B40-4ED5-8A1B-4B47A81119D7 Q36040463-AC993C5A-1A17-4B2E-85F4-F2D807B3E62A Q36081720-D09753DC-00CB-49EB-AE1D-2EF5593B3351 Q36254297-1A9B965B-A1D2-4C7A-8B46-B439D7BF3B97 Q36394925-978006EC-B775-4932-A516-452A7CCB909A Q37002153-E1218A7B-8CD1-4372-880B-4245B9A4240D Q37094877-C9B0B0D8-649E-4503-A072-C65033E4FD8E Q37141366-FB23759B-8858-4F8E-B26B-6B51C24087F8 Q37724301-EAF6BCE0-E56F-42B7-AA84-F21F1C9F2506 Q38134759-71211870-DB8A-4C9E-B6A8-0A28215853A5 Q38151549-A879D452-F682-4479-9920-629A1EABF058 Q39113994-DF81CEF9-1998-45F5-9638-F2FE46475D5B Q39242592-724B3750-16BF-4023-BA1F-F8A039032DD8 Q41288150-B0FAD724-9A0D-48EE-B874-78915D873129 Q42320465-45A1DFF3-A16B-449B-81FB-4FE39600C9F7 Q46805998-8A745CDD-68D4-4E64-B4A3-FAD9D1CD60E3 Q47300347-B6E37D7F-1860-4169-A167-A697C4B9528C Q50854241-7936D744-6DBE-4315-B6F4-231979ACD7F7 Q51512425-62737878-A086-43EF-AD33-ABDD3011E59E Q53820259-DAF8CB18-0740-4CEF-BC4C-10C4F0AEE2DE Q55242101-5BAAA7E4-42FA-4C69-9A7D-89DB2552B8BB Q55413334-D677A2D2-3B7F-45DF-9FFF-32315DC15403 Q57106044-A2560AFA-33AB-4D94-8033-FD2A1A53BF82

P2860

Liposomal Doxorubicin in the treatment of breast cancer patients: a review

http://www.wikidata.org/entity/Q36748268

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Liposomal Doxorubicin in the treatment of breast cancer patients: a review

@en

type

label

Liposomal Doxorubicin in the treatment of breast cancer patients: a review

@en

prefLabel

Liposomal Doxorubicin in the treatment of breast cancer patients: a review

@en

P1433

Q36748268-B0D5DB7C-5B2F-41CE-8070-64328F01698D

P1476

Q36748268-80CB8273-61E3-4532-B056-891495B1F4CC

P2093

Q36748268-100374D2-A28D-405F-A69F-5C67E4E9C78A

Q36748268-29F80CF7-720F-427E-BCCD-85DE793603F2

Q36748268-4ACF791E-2E57-42F0-8DE5-2A0211A2570C

Q36748268-9DCDC59F-0166-4DD6-A4AB-9FD593DCCF7E

Q36748268-B3D9BA1C-E123-4C56-9B36-8BB623BD5CFC

Q36748268-EF6E9E8E-9ABD-4F5B-9CB6-3632EAE5056F

Q36748268-F0625250-092E-4E24-AAD0-4DB67C8C2D3C

Q36748268-F459510B-DFB5-4B5C-8E7D-A5B4B1D8B2C7

P2860

Q36748268-005A0F1E-2004-45D5-A235-6803E889C602

Q36748268-00DE01F1-9099-48C7-90CB-9F894AF633AD

Q36748268-0326554D-1604-4FC9-AFC7-DAB65D73F936

Q36748268-0FD9611C-2A67-4C82-8C15-CAABF4D7B577

Q36748268-1647B62B-09DD-4D4C-AD4A-D0338C1DF216

Q36748268-18BC435B-C1F3-49D8-A00C-6C49757D6B24

Q36748268-19437C45-72D8-4F6D-BE88-6994118BAC24

Q36748268-1DF7FD2C-139C-41E2-9353-489C3A9E299D

Q36748268-2272D029-0C6E-4B37-B21C-B971D67B1E72

Q36748268-290353E7-6198-4666-A7FD-81659D9289C5

P304

Q36748268-5571A284-914D-444C-983E-07D81CD9035E

P31

Q36748268-C3AAEAFB-A872-4E8B-BBDD-CDBBC5E79FDE

P356

Q36748268-5A2D50D1-6DC5-492E-A3CA-E35B4F3F3360

P478

Q36748268-9761291B-5622-4D30-A4F7-AA0A721651F5

P577

Q36748268-2C2012E8-A3C9-434B-9CED-72EA27CA7AE9

P5875

Q36748268-1C8565BA-18BF-4FC0-9852-D363A46B7D3D

P698

Q36748268-313A9B10-4780-4849-A021-60F0AC3C144D

P932

Q36748268-23808012-8256-4B8C-B33E-3AE35196E275

P356

P1433

Journal of Drug Delivery

P1476

Liposomal Doxorubicin in the treatment of breast cancer patients: a review

@en

P2093

Alba Hernández

http://www.w3.org/2001/XMLSchema#string

Angel Artal

http://www.w3.org/2001/XMLSchema#string

Antonio Antón Torres

http://www.w3.org/2001/XMLSchema#string

Juan Lao

http://www.w3.org/2001/XMLSchema#string

Julia Madani

http://www.w3.org/2001/XMLSchema#string

María Alvarez

http://www.w3.org/2001/XMLSchema#string

Roberto Pazo-Cid

http://www.w3.org/2001/XMLSchema#string

Teresa Puértolas

http://www.w3.org/2001/XMLSchema#string

P2860

Different anthracycline derivates for reducing cardiotoxicity in cancer patients

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Molecular portraits of human breast tumours

Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans

Risk factors for doxorubicin-induced congestive heart failure

Anthracycline cardiomyopathy monitored by morphologic changes

Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review

Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.

A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer.

P304

456409

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2013/456409

http://www.w3.org/2001/XMLSchema#string

P478

2013

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236600905

http://www.w3.org/2001/XMLSchema#string

P698

23634302

http://www.w3.org/2001/XMLSchema#string

P932

3619536

http://www.w3.org/2001/XMLSchema#string